Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 374

The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update

Open access
Allison, Kimberly H., Hammond, M. Elizabeth H., Dowsett, Mitchell, McKernin, Shannon E., Carey, Lisa A., Fitzgibbons, Patrick L., Hayes, Daniel F., Lakhani, Sunil R., Chavez-MacGregor, Mariana, Perlmutter, Jane, Perou, Charles M., Regan, Meredith M., Rimm, David L., Symmans, W. Fraser, Torlakovic, Emina E., Varella, Leticia, Viale, Giuseppe, Weisberg, Tracey F., McShane, Lisa M., Wolff, Antonio C.·2020·Archives of Pathology & Laboratory Medicine

Abstract

Purpose.—: To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer guideline. Methods.—: A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. Recommendations.—: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose. Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment. A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive. Additional strategies recommended to promote optimal performance, interpretation, and reporting of cases with an initial low to no ER staining result include establishing a laboratory-specific standard operating procedure describing additional steps used by the laboratory to confirm/adjudicate results. The status of controls should be reported for cases with 0% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breast-cancer-guidelines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5858/arpa.2019-0904-sa

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 129 references

Cited by

See all 374

Metadata

Authors
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., Perou, C. M., Regan, M. M., Rimm, D. L., Symmans, W. F., Torlakovic, E. E., Varella, L., Viale, G., Weisberg, T. F., McShane, L. M., & Wolff, A. C.
Venue
Archives of Pathology & Laboratory Medicine
Published
2020-01-13
Volume
144
Issue
5
Pages
545-563
ISSN
  • 0003-9985 (ISSN-L)
  • 1543-2165
OpenAlex
W2999744434
Cited by
374
References
129
FWCI
15.39
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. https://app.cochat.ai/papers/10.5858/arpa.2019-0904-sa
The paper
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., Perou, C. M., Regan, M. M., Rimm, D. L., Symmans, W. F., Torlakovic, E. E., Varella, L., Viale, G., Weisberg, T. F., McShane, L. M., & Wolff, A. C. (2020). Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Archives of Pathology & Laboratory Medicine. https://doi.org/10.5858/arpa.2019-0904-sa

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.